Mandate

Vinge advised Valneva SE in connection with its acquisition of Crucell Sweden AB

January 18, 2016

Vinge, in cooperation with Dechert LLP as lead legal advisor, advised Valneva SE in connection with its acquisition of Crucell Sweden AB, the Nordics vaccine distribution business of the seller (Crucell Holland B.V.) and all assets, licenses and privileges related to Dukoral®, a vaccine against cholera and, in some countries, diarrhea caused by ETEC. Valneva is a Lyon based biotechnology company listed at Euronext Paris and at the Vienna stock exchange. The consideration amounted to € 45 million and the acquisition was completed on 9 February 2015.

Vinge advised Valneva on Swedish law matters. Vinge’s team consists of M&A partner Peter Sundgren, associates Johanna Wiberg and Kajsa Hallner (M&A), Anders Morén and Josefin Larsson (banking & finance), and Amanda Knutsson and David Andersson (capital markets).

Related

Vinge has advised private equity firm Stirling Square Capital Partners

Vinge has advised private equity firm Stirling Square Capital Partners in connection with its acquisition of a majority stake in Infobric, a leading provider of software solutions for the construction industry, from Summa Equity.
September 22, 2023

Vinge advises Stendörren in connection with issuance of green notes and tender offer

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
September 21, 2023

Vinge has advised Elektroskandia in connection with its majority investment in Aprilice

Vinge has advised Elektroskandia (a Sonepar company) in connection with its acquisition of 70% of the shares in Aprilice, one of the leading solar energy platforms in Northern Europe.
September 20, 2023